FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?
Expert Review of Clinical Pharmacology · 2025-02 · 18 (1-2) · 1-3
DOI: 10.1080/17512433.2024.2447779 ↗Kurz gefasst
Editorial in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 02.01.2025. Verfasst von Jane E Rogers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
1. Esophageal cancer represents the seventh most common cancer diagnosed and the sixth leading cause of cancer death [1]. The incidence varies widely based on geographic location. EC is separated b...
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
- Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
Zitieren
APA
Rogers, J. E., Leung, M., & Ajani, J. A. (2025). FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?. Expert Review of Clinical Pharmacology, 18(1-2), 1-3. https://doi.org/10.1080/17512433.2024.2447779
Vancouver
Rogers JE, Leung M, Ajani JA. FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?. Expert Review of Clinical Pharmacology. 2025;18(1-2):1-3. doi:10.1080/17512433.2024.2447779
BibTeX
@article{Rogers2025,
author = {Rogers, Jane E and Leung, Michael and Ajani, Jaffer A},
title = {FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
volume = {18},
number = {1-2},
pages = {1--3},
doi = {10.1080/17512433.2024.2447779}
}
EUVIMED